The Zhitong Finance App learned that on Thursday, cardiovascular pharmaceutical company Braveheart Bio (BRVE.US) entered the US stock market. As of press release, the stock had risen more than 75% to 31.405 US dollars. The IPO price is $18. Established in 2024, Braveheart Bio is a late-clinical biopharmaceutical company focused on developing innovative treatments for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. The company's core drug candidate BHB-1893 (also known as HRS-1893) is an oral small-molecule cardiomyosin inhibitor that specifically inhibits myocardial myosin ATPase activity, normalizes myocardial contractile performance, reduces left ventricular hypertrophy, and improves diastolic compliance. The drug obtained an exclusive global license (excluding Greater China) from Jiangsu Hengrui Pharmaceutical in China in September 2025.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.